Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Characteristics of cancer and non-cancer cohorts

From: Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents

  Cancer cohort Non-cancer cohort
n= 9,862 n= 15,483
n (%) n (%)
Sex
  Female 3,116 (31.6) 7,521 (48.9)
  Male 6,746 (68.4) 7,962 (51.4)
Age at death
  65–74 294 (3.0) 254 (1.7)
  75–84 4,075 (41.3) 5,028 (32.5)
  85–94 5,215 (52.9) 9,232 (59.6)
  95–104 277 (2.8) 958 (6.2)
  ≥105 1 (0.0) 11 (0.1)
Year of death
  2005 1,204 (12.2) 1,772 (11.4)
  2006 2,236 (22.7) 3,199 (20.7)
  2007 2,351 (23.8) 3,473 (22.4)
  2008 2,133 (21.6) 3,619 (23.4)
  2009 1,938 (19.7) 3,420 (22.1)
Location of residence at death (remoteness area)
  Major cities 6,147 (62.3) 9,530 (61.6)
  Inner regional 2,777 (28.2) 4,400 (28.4)
  Outer regional 872 (8.8) 1,410 (9.1)
  Remote 39 (0.4) 81 (0.5)
  Very remote 5 (0.1) 2 (0.0)
  Missing 22 (0.2) 60 (0.4)
Socioeconomic disadvantage index at death
  (Most disadvantaged) 1–2 1,160 (11.8) 1,862 (12.0)
  3–4 2,831 (28.7) 4,470 (28.9)
  5–6 2,032 (20.6) 3,085 (19.9)
  7–8 1,418 (14.4) 2,248 (14.5)
  (Least disadvantaged) 9–10 2,019 (20.5) 3,183 (20.6)
  Missing 402 (4.1) 635 (4.1)
Charlson comorbidity burden1
  0 3,105 (31.5) 4,451 (28.8)
  1–2 1,500 (15.2) 2,068 (13.4)
  ≥3 1,713 (17.4) 1,578 (10.2)
  No hospitalizations during calculation period (cannot calculate) 3,544 (35.9) 7,386 (47.7)
RxRisk comorbidity burden2
  0 461 (4.7) 846 (5.5)
  1–2 1,298 (13.2) 2,130 (13.8)
  3–5 3,865 (39.2) 6,104 (39.4)
  ≥6 4,238 (43.0) 6,403 (41.4)
  1. 1Calculated using hospitalizations in the 12-month period before the last 6 months of life (months 18 to 7 before death).
  2. 2Calculated using dispensing history in the 6-month period before the last 6 months of life (months 12 to 7 before death).